b Eravacycline and comparators were tested against carbapenem-and tigecycline-resistant Enterobacteriaceae and Acinetobacter isolates received at the United Kingdom's national reference laboratory. Eravacycline MICs correlated closely with those of tigecycline but mostly were around 2-fold lower; both molecules retained full activity against isolates with high-level tetracycline and minocycline resistance. MIC 90 s of eravacycline and tigecycline were raised ca. 2-fold for carbapenem-resistant Enterobacteriaceae compared with carbapenem-susceptible controls, probably reflecting subsets of isolates with increased efflux.
C
arbapenemase-producing Enterobacteriaceae (CPE) present a growing challenge, as do strains that combine porin loss with AmpC or extended-spectrum ␤-lactamase (ESBL) activity. Many are susceptible only to tigecycline, colistin, and fosfomycin.
Tigecycline evades the Tet(A) to Tet(E) efflux pumps and ribosome protection mechanisms that cause most tetracycline resistance, but its utility as monotherapy is compromised by (i) disputed breakpoints for Enterobacteriaceae (U.S. Food ( ii) a lack of breakpoints for Acinetobacter baumannii, (iii) low serum drug peaks, and (iv) an FDA warning of excess mortality (1) (2) (3) (4) (5) . Despite these concerns, case series suggest that patients with severe CPE infections respond better to colistin-tigecycline combinations than to colistin alone (6, 7) .
Eravacycline (TP-434) is a new synthetic "fluorocycline" active against most Gram-negative species (8) , again including those with acquired tetracycline efflux pumps and ribosomal protection. It is well tolerated, with simpler pharmacokinetics than tigecycline and higher serum drug levels (9) . At 1 mg/kg of body weight intravenous (i.v.) every 12 h (q12h), eravacycline proved noninferior to ertapenem in a phase III trial for complicated intra-abdominal infection (9) . A second phase III trial failed to establish eravacycline (1.5 mg/kg i.v. q24h, with step-down to 200 mg oral [p.o.] q12h from day 3) as noninferior to levofloxacin in complicated urinary tract infection, although revised regimens continue to merit study (10) . Against this background, we tested eravacycline in vitro against circulating carbapenem-resistant Enterobacteriaceae and A. baumannii isolates from the United Kingdom and sought to define the interrelationship between eravacycline and tigecycline MICs. The test organisms (n ϭ 369) (Table 1) were recent submissions from United Kingdom clinical diagnostic laboratories to the national reference laboratory. For Enterobacteriaceae, "carbapenem resistant" was defined as resistant at least to ertapenem, as tested by British Society for Antimicrobial Chemotherapy (BSAC) agar dilution methodology (11) . Carbapenemase genes were identified by PCR (12) . Carbapenem resistance contingent on porin loss plus AmpC or ESBL activity was inferred from the absence of carbapenemase genes together with appropriate cefotaxime-cloxacillin or oxyimino-cephalosporin-clavulanate synergy. Isolates included specifically for tigecycline nonsusceptibility (Tig r ) (Table 1) were chosen based on MICs of Ն2 g/ml by BSAC agar dilution; other organisms were chosen without reference to previous tigecycline MICs. Controls were chosen as carbapenem and tigecycline susceptible and as lacking ESBLs or copious AmpC. MICs were determined by CLSI broth microdilution (13) using plates (Thermofisher, Oakwood Village, OH) containing eravacycline and tigecycline (both 0.06 to 16 g/ml), minocycline (0.12 to 64 g/ml), and tetracycline (0.25 to 16 g/ml). Results were reviewed against EUCAST breakpoints (http://www.eucast.org [values as of the end of 2015]) since EUCAST, unlike CLSI, has values for tigecycline as the major comparator.
Meropenem (0.03 to 128 g/ml), amikacin (0.25 to 128 g/ ml), levofloxacin (0.03 to 32 g/ml), colistin (0.12 to 32 g/ml), baumannii strains, the proportions nonsusceptible were as follows: amikacin, 66%; colistin, 8%; levofloxacin, 96%; and meropenem, 100%; A. baumannii is inherently resistant to fosfomycin. All of the control Enterobacteriaceae were susceptible to comparators, except (i) Proteeae and Serratia spp. were inherently resistant to colistin, (ii) one Escherichia coli isolate was resistant to colistin at EUCAST's 2-g/ml breakpoint, and (iii) a few isolates were resistant to fosfomycin. Two of the 10 carbapenem-susceptible A. baumannii controls were nonsusceptible to amikacin, and one was nonsusceptible to levofloxacin. Eravacycline MICs for the Enterobacteriaceae series (excluding Proteeae, discussed below) were unimodally distributed, as were those of tigecycline (Table 2) . Minocycline distributions were unimodal, but with more positive skew (i.e., a wider spread of MICs above than below the mode) than for eravacycline and tigecycline and with a few highly resistant isolates. MIC distributions of tetracycline were bimodal. Although their distributions overlapped considerably, the MICs of eravacycline were mostly 2-fold lower than those of tigecycline, with modes at 0.25 to 0.5 g/ml, according to the species and resistance group, versus 0.5 to 1 g/ml. MIC 50 s of eravacycline (underlined in Table 2 ) for the carbapenem-resistant Enterobacteriaceae groups mostly were 2-fold higher than those for carbapenem-susceptible control strains, while MIC 90 s (boldface in Table 2 ) were 2-or 4-fold higher-a differential also evident for tigecycline MIC 90 s (not MIC 50 s). These raised summary MICs partly reflected a larger proportion of Klebsiella versus E. coli isolates among the carbapenem-resistant isolates than the controls (Table 1) , coupled with a general trend for Klebsiella to be less susceptible to eravacycline and tigecycline than E. coli (Table 3) . Nevertheless, the pattern persisted if only Klebsiella spp. were considered, indicating that a subset of the carbapenem-resistant K. pneumoniae isolates had reduced eravacycline and tigecycline susceptibility.
Among the 30 carbapenemase-producing Enterobacteriaceae specifically included as tigecycline nonsusceptible based on prior BSAC agar testing, 18 were confirmed resistant, with MICs of 4 to 16 g/ml, and another 6 as intermediate, with MICs of 2 g/ml.
MICs of eravacycline remained below those of tigecycline, but with 16 values in the range 4 to 16 g/ml ( Table 2) .
The 15 Proteeae isolates (Table 1 ) comprised 6 Morganella morganii, 5 Providencia rettgeri, and 3 P. stuartii isolates and 1 Proteus mirabilis isolate: 10 isolates had carbapenemases, 8 of which were NDM types. All 15 organisms were resistant to classical tetracyclines. Two were susceptible at tigecycline's EUCAST breakpoint of Յ1 g/ml, four intermediate (MIC, 2 g/ml), and nine resistant, with MICs of Ͼ2 g/ml. For eravacycline, 12/15 MICs were from 1 to 4 g/ml (Table 3) , with 10/15 values 2-fold below those for tigecycline.
MICs of eravacycline and tigecycline for the carbapenem-resistant A. baumannii series were unimodally distributed (Table 4) , with eravacycline values mostly 2-to 4-fold below tigecycline, clustering at 0.5 to 1 g/ml versus 1 to 4 g/ml. MICs of minocycline were widely scattered, with most isolates highly resistant to tetracycline. As with Enterobacteriaceae, eravacycline and tigecycline MIC 50 s and MIC 90 s for the carbapenem-resistant groups exceeded those for the susceptible controls. Five A. baumannii isolates, all with OXA-23 carbapenemase, were included based on previously found tigecycline resistance: four "retained" tigecycline MICs of 8 to 16 g/ml, and MICs of eravacycline for these were 4 to 8 g/ml.
Two key findings emerge. First, eravacycline is 2-to 4-fold more active than tigecycline against carbapenem-resistant Entero bacteriaceae and A. baumannii isolates, but with qualitatively similar behaviors, leading to close correlation between MICs of both molecules (Fig. 1) . Second, although (unsurprisingly) little relationship existed between eravacycline MICs and specific carbapenem resistance mechanisms, MIC 90 s of eravacycline and tigecycline were 2-to 4-fold higher for carbapenem-resistant Enterobacteriaceae and A. baumannii isolates than for the carbapenem-susceptible controls, with a similar MIC 50 shift for eravacycline. The likely explanation is that a subset of carbapenem-resistant isolates have upregulated endogenous efflux or reduced permeability, a view supported by a recent Chinese study reporting frequent upregulation of the AcrAB pump in K. pneumoniae isolates with KPC enzymes (14) . Upregulation of such pumps is the principal mode of tigecycline resistance in Enterobacteriaceae and A. baumannii (15) and accounts for the intrinsic resistance of Proteeae (16) .
The small but consistent gains in activity against carbapenemresistant Enterobacteriaceae and A. baumannii isolates compared with tigecycline, coupled with higher serum drug levels, better tolerability, and more straightforward pharmacokinetics, may translate to an advantage for eravacycline, and clinical investigation is warranted.
